Biosimilar Antibodies

Labetuzumab Biosimilar – Anti-CEACAM5 mAb – Research Grade, ProteoGenix, PX-TA1048

Description of Labetuzumab Biosimilar - Anti-CEACAM5 mAb - Research Grade Introduction Labetuzumab Biosimilar, also known as Anti-CEACAM5 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Labetuzumab. This antibody specifically targets the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), which is overexpressed in various types of cancer. In this article, we will discuss the structure, activity, and potential applications of Labetuzumab Biosimilar in the field of cancer research. Structure of Labetuzumab Biosimilar Labetuzumab Biosimilar is a recombinant, humanized IgG1 monoclonal antibody that has been engineered to have a similar structure to the original Labetuzumab. It consists of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains contain constant regions (Fc) and variable regions (Fab), while the light chains contain only variable regions. The variable regions are responsible for binding to the target antigen, CEACAM5, while the constant regions are involved in effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Labetuzumab Biosimilar Labetuzumab Biosimilar binds specifically to CEACAM5, a glycoprotein that is overexpressed in a variety of cancers, including colorectal, pancreatic, and lung cancer. This binding inhibits the growth and spread of cancer cells by blocking the interaction between CEACAM5 and its ligands, which are involved in cell adhesion and signaling pathways. Additionally, Labetuzumab Biosimilar can induce ADCC and CDC, leading to the destruction of cancer cells by the immune system. Potential Applications of Labetuzumab Biosimilar Labetuzumab Biosimilar has shown promising results in preclinical and clinical studies as a potential therapeutic agent for various types of cancer. Here are some potential applications of this antibody: 1. Treatment of Colorectal Cancer CEACAM5 is highly expressed in colorectal cancer cells, making it an ideal target for Labetuzumab Biosimilar. In a phase II clinical trial, Labetuzumab Biosimilar showed promising results in combination with chemotherapy in patients with metastatic colorectal cancer. It significantly improved progression-free survival and overall survival compared to chemotherapy alone. 2. Treatment of Pancreatic Cancer Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. CEACAM5 is overexpressed in pancreatic cancer cells, and Labetuzumab Biosimilar has shown efficacy in preclinical studies. A phase I clinical trial is currently ongoing to evaluate the safety and efficacy of Labetuzumab Biosimilar in combination with chemotherapy in patients with advanced pancreatic cancer. 3. Treatment of Lung Cancer CEACAM5 is also overexpressed in lung cancer cells, and Labetuzumab Biosimilar has shown promising results in preclinical studies. A phase II clinical trial is currently ongoing to evaluate the safety and efficacy of Labetuzumab Biosimilar in combination with chemotherapy in patients with advanced non-small cell lung cancer. 4. Research Tool for Cancer Studies In addition to its potential therapeutic applications, Labetuzumab Biosimilar can also serve as a valuable research tool for studying the role of CEACAM5 in cancer development and progression. It can be used in various techniques such as flow cytometry, immunohistochemistry, and Western blotting to detect and quantify CEACAM5 expression in cancer cells. Conclusion Labetuzumab Biosimilar is a promising biosimilar of the original Labetuzumab, with a similar structure and activity. Its specific targeting of CEACAM5, a protein overexpressed in various types of cancer, makes it a potential therapeutic agent for colorectal, pancreatic, and lung cancer. Furthermore, it can also serve as a valuable research tool for studying the role of CEACAM5 in cancer. Further clinical trials are needed to fully evaluate the efficacy and safety of Labetuzumab Biosimilar, but it holds great

Lacnotuzumab Biosimilar – Anti-CSF1, MCSF mAb – Research Grade, ProteoGenix, PX-TA1466

Description of Lacnotuzumab Biosimilar - Anti-CSF1, MCSF mAb - Research Grade The Structure of Lacnotuzumab Biosimilar – Anti-CSF1, MCSF mAb Lacnotuzumab Biosimilar, also known as Anti-CSF1, MCSF mAb, is a monoclonal antibody that specifically targets the colony stimulating factor 1 (CSF1) protein. This protein plays a critical role in regulating the growth, differentiation, and survival of macrophages, a type of white blood cell involved in immune response and tissue repair. The structure of Lacnotuzumab Biosimilar is composed of two identical heavy chains and two identical light chains, each with a specific amino acid sequence. These chains are connected by disulfide bonds, forming a Y-shaped molecule with two antigen-binding sites. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL) and one variable domain (VL). The variable domains of Lacnotuzumab Biosimilar are responsible for its high specificity and affinity for the CSF1 protein. The antigen-binding sites on the tips of the Y-shaped molecule are able to recognize and bind to specific regions on the CSF1 protein, effectively blocking its activity. The Activity of Lacnotuzumab Biosimilar Lacnotuzumab Biosimilar is a potent inhibitor of CSF1, as it blocks the interaction between CSF1 and its receptor on the surface of macrophages. This prevents the activation of downstream signaling pathways that are necessary for macrophage survival, proliferation, and differentiation. By inhibiting CSF1, Lacnotuzumab Biosimilar can modulate the activity of macrophages in various physiological and pathological conditions. For example, in cancer, macrophages are known to promote tumor growth and metastasis. By targeting CSF1, Lacnotuzumab Biosimilar can disrupt the tumor-promoting activity of macrophages, potentially slowing down the progression of cancer. Furthermore, CSF1 is also involved in the regulation of bone metabolism. By blocking its activity, Lacnotuzumab Biosimilar can potentially be used to treat diseases such as osteoporosis and rheumatoid arthritis, where excessive bone resorption by macrophages is a contributing factor. The Application of Lacnotuzumab Biosimilar Lacnotuzumab Biosimilar is currently being developed as a therapeutic agent for various diseases, including cancer and bone disorders. It is being studied in preclinical and clinical trials to evaluate its safety and efficacy in these conditions. In cancer, Lacnotuzumab Biosimilar has shown promising results in preclinical studies, demonstrating its ability to inhibit tumor growth and metastasis. Clinical trials are underway to evaluate its efficacy in various types of cancer, including breast cancer, lung cancer, and melanoma. In bone disorders, Lacnotuzumab Biosimilar has shown potential in preclinical studies to prevent bone loss and promote bone formation. Clinical trials are currently ongoing to evaluate its effectiveness in treating osteoporosis and rheumatoid arthritis. In addition to its therapeutic potential, Lacnotuzumab Biosimilar is also being used as a research tool to study the role of CSF1 in various diseases and to develop new treatments targeting this protein. The Future of Lacnotuzumab Biosimilar Lacnotuzumab Biosimilar has shown promising results in preclinical and early clinical studies, and its potential as a therapeutic agent for cancer and bone disorders is being further explored. As more research is conducted, it is expected that the use of this antibody will expand to other diseases where CSF1 plays a critical role. Furthermore, the development of Lacnotuzumab Biosimilar also highlights the importance of targeting specific proteins and pathways in disease treatment. With the advancement of biotechnology and the understanding of disease mechanisms, more targeted therapies like Lacnotuzumab Biosimilar are likely to be developed in the future, providing more effective and personalized treatment options for patients.

Lanadelumab Biosimilar – Anti-KLKB1 mAb – Research Grade, ProteoGenix, PX-TA1423

Description of Lanadelumab Biosimilar - Anti-KLKB1 mAb - Research Grade General information on Anti-KLKB1[Homo sapiens] (Lanadelumab) Monoclonal Antibody Lanadelumab is a human IgG1 monoclonal antibody taht targets KLKB1. It is used to treat Hereditary angioedema.

Landogrozumab Biosimilar – Anti-MSTN, GDF8 mAb – Research Grade, ProteoGenix, PX-TA1403

Description of Landogrozumab Biosimilar - Anti-MSTN, GDF8 mAb - Research Grade General information on Anti-MSTN/GDF8[Homo sapiens] (Landogrozumab) Monoclonal Antibody Landogrozumab has been investigated for the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.

Latarcibart Biosimilar – Research Grade, ProteoGenix, PX-TA2489-100

Latikafusp Biosimilar – Anti-PDCD1 mAb – Research Grade, ProteoGenix, PX-TA1856

Description of Latikafusp Biosimilar - Anti-PDCD1 mAb - Research Grade Introduction Latikafusp Biosimilar, also known as Anti-PDCD1 mAb – Research Grade, is a novel therapeutic antibody targeting the programmed cell death protein 1 (PDCD1) pathway. This biosimilar is designed to mimic the function of the original Latikafusp antibody, which has shown promising results in clinical trials for the treatment of various cancers. In this article, we will discuss the structure, activity, and potential applications of Latikafusp Biosimilar in the field of cancer therapy. Structure of Latikafusp Biosimilar Latikafusp Biosimilar is a monoclonal antibody (mAb) that specifically binds to the PDCD1 receptor on the surface of immune cells. It is a chimeric antibody, meaning it is composed of both human and mouse components. The variable region of the antibody is derived from a mouse antibody, while the constant region is humanized to minimize potential immune reactions in patients. This structure allows for high specificity and affinity towards the PDCD1 receptor, making it a highly effective therapeutic agent. Activity of Latikafusp Biosimilar The PDCD1 pathway plays a crucial role in regulating the immune response to cancer cells. PDCD1, also known as PD-1, is a receptor expressed on the surface of T cells, B cells, and natural killer cells. When activated by its ligands, PD-L1 or PD-L2, PDCD1 inhibits the function of these immune cells, allowing cancer cells to evade detection and destruction by the immune system. Latikafusp Biosimilar works by blocking the interaction between PDCD1 and its ligands, thus restoring the anti-tumor activity of immune cells. Potential Applications of Latikafusp Biosimilar The potential applications of Latikafusp Biosimilar are vast, as the PDCD1 pathway is involved in the development and progression of various types of cancer. Clinical trials have shown promising results in the treatment of melanoma, non-small cell lung cancer, and renal cell carcinoma. Furthermore, preclinical studies have also demonstrated the potential of Latikafusp Biosimilar in combination with other cancer therapies, such as chemotherapy and radiation, to enhance their efficacy. Mechanism of Action The mechanism of action of Latikafusp Biosimilar involves blocking the interaction between PDCD1 and its ligands, PD-L1 and PD-L2. This prevents the inhibitory signal from being transmitted to immune cells, allowing them to recognize and attack cancer cells. Additionally, the binding of Latikafusp Biosimilar to PDCD1 may also trigger an immune response, further enhancing the anti-tumor activity of immune cells. Advantages of Latikafusp Biosimilar Compared to the original Latikafusp antibody, the biosimilar version offers several advantages. Firstly, it is more cost-effective, making it more accessible to patients. Secondly, the humanized constant region reduces the risk of immune reactions, making it a safer option for patients. Lastly, the biosimilar can be produced in larger quantities, ensuring a stable and reliable supply for clinical use. Conclusion In conclusion, Latikafusp Biosimilar is a promising therapeutic agent in the field of cancer therapy. Its specific targeting of the PDCD1 pathway and potential applications in various types of cancer make it a valuable addition to the current arsenal of cancer treatments. With ongoing clinical trials and further research, Latikafusp Biosimilar has the potential to improve patient outcomes and contribute to the fight against cancer.

Latozinemab Biosimilar – Anti-SORT1 mAb – Research Grade, ProteoGenix, PX-TA1676

Description of Latozinemab Biosimilar - Anti-SORT1 mAb - Research Grade Introduction Latozinemab Biosimilar, also known as Anti-SORT1 mAb, is a monoclonal antibody that targets SORT1 (sortilin 1) protein. This biosimilar is a research grade product that has been developed for scientific research purposes. In this article, we will discuss the structure, activity, and potential applications of Latozinemab Biosimilar. Structure of Latozinemab Biosimilar Latozinemab Biosimilar is a recombinant humanized monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the target protein, SORT1. The constant regions are responsible for mediating effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Latozinemab Biosimilar SORT1 is a type I transmembrane protein that is involved in various cellular processes, including protein trafficking, endocytosis, and signaling. It is overexpressed in many types of cancer, making it a potential therapeutic target. Latozinemab Biosimilar binds to SORT1 with high specificity and affinity, inhibiting its function and leading to cell death. This mechanism of action makes Latozinemab Biosimilar a promising candidate for cancer treatment. In addition to its direct anti-tumor activity, Latozinemab Biosimilar also has the potential to enhance the effectiveness of other cancer therapies. SORT1 has been shown to play a role in drug resistance, and by targeting this protein, Latozinemab Biosimilar may sensitize cancer cells to chemotherapy and other targeted therapies. Potential Applications of Latozinemab Biosimilar Latozinemab Biosimilar has shown promising results in preclinical studies, demonstrating its potential as a therapeutic agent for various types of cancer. Some of the potential applications of Latozinemab Biosimilar include: 1. Treatment of Solid Tumors SORT1 is highly expressed in solid tumors, including breast, lung, and pancreatic cancer. Latozinemab Biosimilar has shown significant anti-tumor activity in preclinical studies of these cancers, making it a potential treatment option for patients. 2. Combination Therapy As mentioned earlier, Latozinemab Biosimilar has the potential to enhance the efficacy of other cancer therapies. It can be used in combination with chemotherapy, targeted therapies, and immunotherapies to improve treatment outcomes and overcome drug resistance. 3. Diagnostic Tool SORT1 is not only a therapeutic target but also a potential biomarker for cancer. Latozinemab Biosimilar can be used as a diagnostic tool to detect SORT1 expression in tumors, which can help in patient selection for treatment and monitoring treatment response. 4. Research Tool Latozinemab Biosimilar is a research grade product, making it a valuable tool for scientific research. It can be used to study the role of SORT1 in cancer development and progression, as well as to evaluate the potential of SORT1 as a therapeutic target in other diseases. Conclusion In summary, Latozinemab Biosimilar is a promising monoclonal antibody that targets SORT1 protein. Its unique mechanism of action and potential applications make it a valuable asset in the fight against cancer. Further clinical studies are needed to evaluate its safety and efficacy in humans, but the preclinical data is highly encouraging. Latozinemab Biosimilar has the potential to become a valuable therapeutic option for patients with cancer, and its research grade version can aid in advancing our understanding of SORT1 and its role in disease.

Lecomkafusp alfa Biosimilar – Research Grade, ProteoGenix, PX-TA2491-100

Lenercept Biosimilar – Anti-TNF fusion protein – Research Grade, ProteoGenix, PX-TA2017

Description of Lenercept Biosimilar - Anti-TNF fusion protein - Research Grade Introduction to Lenercept Biosimilar Lenercept Biosimilar is a research grade anti-TNF fusion protein that has been developed as a potential therapeutic agent for various inflammatory and autoimmune diseases. It is a biosimilar of etanercept, a widely used anti-TNF drug, and is designed to have similar structure and activity. Structure of Lenercept Biosimilar Lenercept Biosimilar is a recombinant fusion protein consisting of two components – a soluble TNF receptor and the Fc region of human immunoglobulin G1 (IgG1). The TNF receptor component is composed of the extracellular domain of the human TNF receptor 2 (TNFR2) and the transmembrane and cytoplasmic domains of the human TNF receptor 1 (TNFR1). The Fc region, on the other hand, is responsible for extending the half-life of the protein in the body by binding to the neonatal Fc receptor (FcRn). The structure of Lenercept Biosimilar is similar to that of etanercept, with the only difference being the source of the TNF receptor component. While etanercept is derived from the extracellular domain of the human TNF receptor 2, Lenercept Biosimilar uses the extracellular domain of the human TNF receptor 2. This difference in the source of the TNF receptor component does not affect the overall structure and function of Lenercept Biosimilar. Mechanism of Action Lenercept Biosimilar acts as a competitive inhibitor of TNF, a pro-inflammatory cytokine that plays a crucial role in various inflammatory and autoimmune diseases. The TNF receptor component of Lenercept Biosimilar binds to TNF with high affinity, preventing it from binding to its natural receptors on the cell surface. This blocks the downstream signaling pathways activated by TNF, thereby reducing inflammation and tissue damage. The Fc region of Lenercept Biosimilar also plays a role in its mechanism of action. It extends the half-life of the protein in the body, allowing for prolonged inhibition of TNF and providing sustained therapeutic effects. Therapeutic Applications Lenercept Biosimilar has shown promising results in preclinical studies and is currently being evaluated for its therapeutic potential in various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and psoriatic arthritis. In a phase I clinical trial, Lenercept Biosimilar was found to be safe and well-tolerated in healthy volunteers. It also showed comparable pharmacokinetic and pharmacodynamic profiles to etanercept, further supporting its potential as a biosimilar of the widely used anti-TNF drug. Further clinical trials are needed to establish the efficacy and safety of Lenercept Biosimilar in treating specific diseases. If successful, it has the potential to provide a more affordable treatment option for patients, as biosimilars are typically priced lower than their reference biologics. Conclusion Lenercept Biosimilar is a promising anti-TNF fusion protein that has been developed as a potential therapeutic agent for various inflammatory and autoimmune diseases. Its structure and mechanism of action are similar to that of etanercept, but with a different source of the TNF receptor component. Further clinical studies will determine its efficacy and safety in treating specific diseases, and if successful, it has the potential to provide a more affordable treatment option for patients.

Lenipagrusin alfa Biosimilar – Research Grade, ProteoGenix, PX-TA2492-100